EMPRISE-interim-analysis
Interim analysis from EMPRISE real-world study shows decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists
Search
EMPERIAL-heart-failure-toplineresults
Update on the EMPERIAL-Reduced and EMPERIAL-Preserved studies, which assess exercise ability in adults with chronic heart failure with reduced and preserved ejection fraction
FOYA_Shanghai
Boehringer Ingelheim’s commercial manufacturing facility in Shanghai has been awarded as “Facility of the Year”
More Stories
World Rabies Day - More Stories
Building blocks of our future
Our global investment projects are the building blocks for improved healthcare and sustainability
Agile working as a mindset
How does an agile mindset foster innovation? Read about collaboration, user-centricity and rapid learning cycles
Phase II trials for patients with bronchiectasis
Bronchiectasis is a chronically progressive pulmonary disease. Boehringer Ingelheim investigates a potential new treatment option in two Phase II trials.
Our goal of transforming the treatment of neuroendocrine carcinomas
Our progress in developing a potential DLL3 targeted immunotherapy for neuroendocrine carcinomas (NECs), including small cell lung cancer (SCLC), large cell NEC of the lung (LCNEC-L) and extrapulmonary NEC (epNEC).
Why cancer care is personal for us
At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.
expanded-collaboration-MD-Anderson
The continued collaboration aims to accelerate the development of KRAS and TRAILR2 compounds in lung cancer
Groundbreaking oncology research zongertinib
Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
Investment social engagements in Cowtribe veterinary startup
Last-mile veterinary delivery social start-up Cowtribe first investment of Boehringer Ingelheim Social Engagements
Social innovation: catalyst for sustainable health solutions
Supporting social innovators drives sustainable health solutions in underserved communities. Learn more about Boehringer Ingelheim Social Engagements.
2024_whitepaper_advancements-in-microbial-manufacturing-of-biopharmaceuticals.pdf
biotherapeutic_technologies_flyer_bio_05-2020.pdf
Biotherapeutic_Technologies_Flyer_BIO_2022.pdf
Retinal_Health_Flyer_BIO-2021_bis-2021-08-03.pdf
Praxbind® – the specific reversal agent to dabigatran.pdf
Experts in microbial technology | Bioxcellence | Boehringer Ingelheim
Meet one BioXcellence expert in microbial development and manufacturing. Explore our broad commercial experience and development competence.
Use of data: "A game changer for our industry"
Data is a game changer for the pharmaceutical industry and will shape our business. Listen to our podcast.
Partnership for first-in-class cancer and CRM treatments
Boehringer Ingelheim partners with OSE Immunotherapeutics to develop first-in-class cancer and CRM treatments
Why we may be more like our pets than we think
The bond between owners and their pets goes beyond physical resemblance as we are increasingly facing similar health problems.
HER2 TKI, Zongertinib
HER2 TKI, Zongertinib
Survodutide Phase III study weight loss
Boehringer Ingelheim to advance survodutide into three global Phase III studies in obesity
SIRPα Cancer Immunology Research
Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.